跳至主要内容
临床试验/NCT04758806
NCT04758806Unknown3 期

Fecal Microbial Transplantation for Corticosteroids Non-responders and Non-eligible Patients With Severe Alcoholic Hepatitis

F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica2 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2018年4月1日最近更新:
适应症

试验速览

阶段
3 期
发起方
入组人数
50
试验地点
2
主要终点
Mortality

研究概览

简要总结

  1. A subtype of Alcoholic hepatitis (AH), named severe alcoholic hepatitis (SAH) is associated with high short-term mortality (J Hepatol, 2019)
  2. The only SAH treatment option - corticosteroids (CS) - are often contraindicated or ineffective (STOPAH Trial)
  3. New treatment modalities for remaining patients are much needed
  4. Fecal microbial transplantation (FMT) is one of the promising therapies
  5. Investigators aimed to see if FMT improves survival in patients admitted with SAH, not responding to-, or non-eligible for CS.

详细描述

  • FMT via upper GI tract is provided to CS non-responders (NR) or non-eligible (NE) adult patients hospitalized with SAH (determined by the Lille-model).
  • Modified version of the Sarin FMT protocol is used with microbiota material procured from unrelated healthy donors.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • consenting, adult
  • severe form of acute alcoholic hepatitis (SAH)
  • non-responder to corticosteroids according to the Lille model
  • patients with SAH not eligible for corticosteroids based on their contraindications

排除标准

  • active infection
  • presence of untreated large / high-risk / bleeding esophageal varices
  • too sick for any therapy / futility (chronic extrahepatic organ failures, no potential for recovery, etc)
  • malignancy except for hepatocellular carcinoma in Milan criteria

结局指标

主要结局

Mortality

时间窗: 1 year

Overall mortality

次要结局

  • Acute on chronic liver failure(In-Hospital)

研究者

发起方
F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica
申办方类型
Other
责任方
Principal Investigator
主要研究者

Ľubomír Skladaný MD, PhD

Head, Department of Internal Medicine and HEGITO Liver Unit, Principal Investigator

F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica

研究点 (2)

Loading locations...

相似试验